Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-12-11
1998-11-24
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 4, 530303, 530304, 530305, A61K 3828, C07K 500, C07K 700, C07K 1600
Patent
active
058406808
ABSTRACT:
The present invention relates to insulin crystals comprising ASP.sup.B28 and protamine, and pharmaceutical preparations containing same. The crystals and preparations exhibit rapid onset and prolonged activity when administered in vivo.
REFERENCES:
patent: 2538018 (1951-01-01), Krayenbuhl et al.
patent: 2801953 (1957-08-01), Dorzbach et al.
patent: 2849370 (1958-08-01), Petersen et al.
patent: 3005023 (1961-10-01), Miller
patent: 3019173 (1962-01-01), Arishima et al.
patent: 3060093 (1962-10-01), Poulsen et al.
patent: 3102077 (1963-08-01), Christensen
patent: 3868358 (1975-02-01), Jackson
patent: 4608364 (1986-08-01), Grau
patent: 5028587 (1991-07-01), Dorschug et al.
patent: 5149777 (1992-09-01), Hansen et al.
patent: 5164366 (1992-11-01), BalSchmidt et al.
patent: 5423641 (1995-06-01), Jonassen et al.
patent: 5461031 (1995-10-01), De Felippis
patent: 5474978 (1995-12-01), Bakaysa et al.
patent: 5514646 (1996-05-01), Chance et al.
patent: 5547930 (1996-08-01), Balschmidt
Howey, et al., Diabetes, 43, 396-402 (Mar. 1994).
Brems, et al., Protein Engineering, 5:6, 519-525 (1992).
Heinemann, et al., Diabetologia, 33, 384-386 (1990).
Kirk-Othmer, Encyclopedia of Chemical Technology 13, 607-614 (1981).
Bruce H. Frank, Text and Slide copies given at the Conference on Insulin, Self Association and Conformational Studies on Human Proinsulin and Insulin Analogs, University of New York, Aug. 29-Sep. 1, 1989.
Fullerton, et al., Biophys. Acta, 214, 141-147 (1970).
Diabetologia, 30, 503A (1987).
Brange, et al., Nature, 333:16 679-682 (Jun. 1988).
Brange et al., Diabetes Care, 13:9, 923-954 (Sep. 1990).
Wollmer, et al., Phenol-Promoted Structural Transformation of Insulin in Solution, from the 2nd Assisi International Symposium on Advanced Models for the Therapy of Insulin-Dependent Diabetes 903-911 (Apr. 1986).
Brange, Galenics of Insulin: The Physico-chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations, Springer-Verlag Berlin Heidelberg, Germany (1987).
Brems, et al, Protein Engineering, 5:6, 527-533 (1992).
Chen, et al., Proc. Natl. Sci. Counc, ROC(A), 6:3 185-189 (1982).
Galloway, et al., Insulin Update, 111-119 91982).
Balschmidt, et al., Acta Cryst, 975-986 (1991).
Dodson, et al., Phil Trans. R. Soc. Lond. A 345, 153-164 (1993).
Wollmer, et al., Biol. Chem. Hoppe-Seyler, 370, 1045-1053 (Sep. 1989).
Derewenda, et al., Nature, 338:13 594-596 (Apr. 1989).
Brader, et al., Biochemistry, 30, 6636-6645 (1991).
Harding, et al., The Crystal Structure of Insulin: II. An Investigation of Rhombohedral Zinc Insulin Crystals and a Report of other Crystalline Forms, Chemical Crystallography Laboratory, South Parks Road, Oxford, England, 212-226 (Nov. 8, 1965).
Brange, et al., Structural Biology, 1, 934-940 (1991).
Scott and Fisher, J. Pharmacol. Exp. Ther., 58:78 (1936).
Hagedorn, et al., J. Am. Med. Assn., 106:177-180 (1936).
Krayenbuhl and Rosenberg, Rep. Steno Mem. Hosp. Nord. Insulinlab., 1:60 (1946).
Goodman, Fermentation and Mutation Development of the Tetracyclines, Springer-Verlag Berlin Heidelberg, New York, Tokyo (1985).
Heinemann, Action Profiles of Rapid-Acting Human Insulin Analogues, Frontiers in Insulin Pharmacology International Symposium, Hamburg, pp. 87-96, Published by Georg Thieme Verlag Stuttgart-New York. Theime Medical Publishers, Inc.-New York (1993).
Brange, et al., Acta Pharm Nord, 4(3):149-158 (1992).
Brems, et al., Altering the Self-Association and Stability of Insulin by Amino Acid Replacement, Protein Folding: In Vivo and In Vitro, American Chemical Society, Chaptr. 19, (1993).
Oral Presentations of the 28th Annual Meeting of the European Association for the Study of Diabetes, Prague, Czechoslavakia (Sep. 8-11, 1992).
J. British Diabetic Association, Posters, p. S33.
Directions in Diabetes Research III, A Lilly Symposium Held in Indianapolis, Indiana, Jun. 10-11, 1993.
Brange, et al., "Design of Novel Insulins with Changed Self-Association and Ligand Binding Properties"GBF Monographs, 12:140-144 (1988).
(Invited Speaker) Self-Association and Conformational Studies on Human Proinsulin and Insulin Analogs, B.H. Frank Lilly Research Laboratories, Eli Lilly & Co., Indiana, IN 46285.
Wiefels, et al., "Insulin kinetics and Dynamics in Insulin--dependent Diabetic Patients after Injections of Human Insulin or the Insulin Analogues X14 and X14+Zn", pp. 97-101. Association for the Study of Diabetes, Abstract, Istanbul, Turkey, Sep. 6-10, 1993.
Lutterman, et al., Glycaemic Control in IDDM Patients during One Day with Injection of Human Insulin or the Insulin Analogues Insulin X14 and Insulin X14 (+Zn), Frontiers in Insulin Pharmacology International Symposium, Hamburg, pp. 102-109, Published by Georg Thieme Verlag Stuttgart-New York, Theime Medical Publishers, Inc.-New York (1993).
Kim, et al.,Biochem. and Biophys. Res. Comm., 186(2):1115-1120 (1992).
Smith, et al., Biopolymers, 32:441-445 (1992).
Smith, et al., Proteins: Structure, Function, and Genetics, 14:401-408 (1992).
Derewenda, et al., British Medical Bulletin, 45 (1):4-18 (1989).
Brange, Current Opinion in Structural Biology, 1:934-940 (1991).
Gregg, Esq. Valeta A.
Harle Jennifer
Novo Nordisk A S
Tsang Cecilia J.
Zelson Esq. Steve T.
LandOfFree
ASP.sup.B28 insulin crystals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ASP.sup.B28 insulin crystals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ASP.sup.B28 insulin crystals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1702143